S&P 500 7,443.28 -0.19% NASDAQ 25,508.07 -0.05% DOW 51,839.26 -0.59% R2K 2,942.43 -0.67% VIX 18.65 -0.64% US 10Y 4.60 +1.26% DXY 100.96 +0.21% BITCOIN 65,274.63 +0.90%
Next Bullish Trade
Sign in
NVAX

Novavax, Inc. NMS · NVAX

$7.88 -0.33 (-4.02%)
Deep pullback · -2.03σ Hot zone Grade C
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · NVAX

Momentum reads · latest daily bar
Last
$7.88
-0.33 (-4.02%)
Mkt cap
$1.3B
Healthcare
RSI(14)
32.2
neutral
Stochastic %K
4.3
oversold
MFI(14)
32.0
neutral
ADX(14)
16.7
weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.1B $-0.0B $-0.0B $-0.0B -6.8% -11.1%
2025-12-31 $0.1B $0.0B $0.0B $-0.0B 11.9% 10.2%
2025-09-30 $0.1B $-0.2B $-0.1B $0.1B -287.3% -115.0%
2025-06-30 $0.2B $0.1B $0.1B $-0.1B 44.5% 42.2%
2025-03-31 $0.7B $0.5B $0.5B $-0.2B 77.8% 77.3%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare NVAX vs peers

Line NVAX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing NVAX no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with NVAX

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-06 -0.06 -0.37 +83.8% -1.4%
2026-02-26 0.11 -0.55 +120.2% -9.4%
2025-11-06 -0.47 -1.13 +58.0% -2.0%
2025-08-06 0.62 0.06 +1000.3% +15.8%
2025-05-08 2.93 0.71 +313.5% -10.2%
2025-02-27 -0.52 -0.51 -1.2% +18.0%
2024-11-12 -0.76 -0.75 -1.9% -8.2%
2024-08-08 0.99 1.70 -41.8% -0.7%
2024-05-10 -1.05 -1.08 +2.8% +47.6%
2024-02-28 -1.44 -0.35 -313.4% +12.0%
2023-11-09 -1.26 -2.21 +43.0% -7.0%
2023-08-08 0.58 -1.16 +149.8% -1.5%
2023-05-09 -3.41 -3.42 +0.3% -5.6%
2023-02-28 -2.28 -1.05 -117.6% -25.9%
2022-11-08 -2.15 1.59 -235.0% -5.2%
2022-08-08 -6.53 5.18 -226.0% -29.6%
2022-05-09 2.56 2.65 -3.5% +1.1%
2022-02-28 -11.18 -1.80 -520.4% +0.4%
2021-11-04 -4.31 -3.55 -21.5% -11.3%
2021-08-05 -4.75 -3.25 -46.2% -19.6%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
NVAX ★ $1B — -14.5 2.2 14.4 -9.0 27.5% -79.1% — 4.52%
LLY — 40.7 25.5 — 30.1 — 82.8% 55.5% 169.9% —
UNH $383B 31.7 18.9 0.9 17.7 3.9 19.5% 0.4% 61.5% 5.95%
JNJ $599B 28.8 19.4 6.1 18.4 7.4 68.1% 6.6% -1.0% —
MRK — 35.1 12.9 — 12.1 6.7 76.7% 4.9% — —
ABBV $448B 124.2 15.6 7.1 17.2 -67.3 72.0% 12.4% -46.2% 4.65%
PFE — 18.9 8.7 — 7.6 — 74.8% 5.4% -10.1% —
TMO — 28.9 19.3 — 21.1 — 40.9% 6.2% 11.3% —

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 48.99%

HolderShares% out
Shah Capital Management 14,845,097 9.03%
Blackrock Inc. 12,844,319 7.81%
State Street Corporation 8,970,518 5.46%
Shaw D.E. & Co., Inc. 7,709,858 4.69%
Vanguard Portfolio Management LLC 7,151,625 4.35%
Vanguard Capital Management LLC 7,130,147 4.34%
Sanofi 6,880,481 4.18%
Bank of America Corporation 6,637,213 4.04%
UBS Group AG 4,477,701 2.72%
Geode Capital Management, LLC 3,898,413 2.37%

Insider activity · 90d

3 buys / 0 sells · ratio 3.0 · Finnhub

  • Rodgers Richard J M 0
  • Rodgers Richard J M 47,370
  • King Rachel K. M 0
  • King Rachel K. M 44,070
  • DOUGLAS RICHARD M 0
  • DOUGLAS RICHARD M 73,220
  • MCGLYNN MARGARET G M 0
  • MCGLYNN MARGARET G M 44,468
  • MOTT DAVID M M 0
  • MOTT DAVID M M 79,770

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$7.0
Mean
$14.11333
High
$25.0
Analysts
9
Recommendation distribution · period 2026-07-01
4
6
2
2
1
Revision trend (2026-04-01 → 2026-07-01): net 7 → 7 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-06-23 OWNERSHIP DOCUMENT view ·
4 2026-06-23 OWNERSHIP DOCUMENT view ·
4 2026-06-23 OWNERSHIP DOCUMENT view ·
4 2026-06-23 OWNERSHIP DOCUMENT view ·
4 2026-06-23 OWNERSHIP DOCUMENT view ·
4 2026-06-23 OWNERSHIP DOCUMENT view ·
4 2026-06-23 OWNERSHIP DOCUMENT view ·
4 2026-06-23 OWNERSHIP DOCUMENT view ·
8-K 2026-06-23 FORM 8-K view ·
8-K 2026-05-06 8-K view ·
10-Q 2026-05-06 10-Q view ·
4 2026-04-28 OWNERSHIP DOCUMENT view ·
DEF 14A 2026-04-27 DEF 14A view ·
4 2026-04-16 OWNERSHIP DOCUMENT view ·
4 2026-03-12 OWNERSHIP DOCUMENT view ·
4 2026-03-09 OWNERSHIP DOCUMENT view ·
4 2026-03-05 OWNERSHIP DOCUMENT view ·
4 2026-03-05 OWNERSHIP DOCUMENT view ·
4 2026-03-05 OWNERSHIP DOCUMENT view ·
4 2026-03-05 OWNERSHIP DOCUMENT view ·
4 2026-03-05 OWNERSHIP DOCUMENT view ·
4 2026-03-03 OWNERSHIP DOCUMENT view ·
4 2026-03-03 OWNERSHIP DOCUMENT view ·
4 2026-03-03 OWNERSHIP DOCUMENT view ·
4 2026-03-03 OWNERSHIP DOCUMENT view ·
8-K 2026-02-26 8-K view ·
10-K 2026-02-26 10-K view ·
4 2026-01-26 OWNERSHIP DOCUMENT view ·
8-K 2026-01-20 FORM 8-K view ·
8-K 2026-01-12 FORM 8-K view ·
4 2025-12-15 OWNERSHIP DOCUMENT view ·
4 2025-11-13 OWNERSHIP DOCUMENT view ·
8-K 2025-11-06 8-K view ·
10-Q 2025-11-06 10-Q view ·
8-K 2025-11-04 FORM 8-K view ·
4 2025-10-30 OWNERSHIP DOCUMENT view ·
8-K 2025-10-22 FORM 8-K view ·
8-K 2025-10-07 FORM 8-K view ·
8-K 2025-08-27 FORM 8-K view ·
8-K 2025-08-27 FORM 8-K view ·
8-K 2025-08-21 FORM 8-K view ·
8-K 2025-08-06 8-K view ·
10-Q 2025-08-06 10-Q view ·
4 2025-06-24 OWNERSHIP DOCUMENT view ·
4 2025-06-24 OWNERSHIP DOCUMENT view ·
4 2025-06-24 OWNERSHIP DOCUMENT view ·
4 2025-06-24 OWNERSHIP DOCUMENT view ·
4 2025-06-24 OWNERSHIP DOCUMENT view ·
4 2025-06-24 OWNERSHIP DOCUMENT view ·
8-K 2025-06-24 FORM 8-K view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
4 2025-06-13 PRIMARY DOCUMENT view ·
4 2025-06-13 PRIMARY DOCUMENT view ·
4 2025-06-13 PRIMARY DOCUMENT view ·
4 2025-06-13 PRIMARY DOCUMENT view ·
8-K 2025-06-11 FORM 8-K view ·
8-K 2025-05-27 FORM 8-K view ·
8-K 2025-05-19 FORM 8-K view ·
8-K 2025-05-08 8-K view ·

About NVAX

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Options picks · NVAX

ITM + OTM ideas from the latest scan

Loading…

Congress trades · NVAX

STOCK Act disclosures

Loading…

SEC filings & insiders · NVAX

EDGAR · live

Loading…

Holders · NVAX

Institutions & insider activity

Loading…